Drug Development
GeoVax Expands Gedeptin Cancer Therapy Development to Additional Solid Tumor Types
GeoVax Labs is expanding its Gedeptin cancer therapy development to include triple negative breast cancer and cutaneous malignancies, building on checkpoint inhibitor momentum and KEYNOTE-689 results to potentially improve outcomes for broader solid tumor patients.
Soligenix Advances Oral Mucositis Treatment SGX942 with Combined Clinical Data Analysis
Soligenix is leveraging positive phase 2 and 3 clinical data to design a second pivotal trial for SGX942, addressing the critical unmet medical need for oral mucositis treatment in cancer patients.
Lantern Pharma Completes Japan Enrollment in Phase 2 Trial for Never-Smoker Lung Cancer Treatment
Lantern Pharma has achieved targeted patient enrollment in Japan for its Phase 2 HARMONIC trial evaluating LP-300 in never-smoker non-small cell lung cancer patients, marking significant progress in addressing an underserved population with high unmet medical need.
Oncotelic Therapeutics CEO's Patent Portfolio and Track Record Position Company for Oncology Market Growth
Oncotelic Therapeutics' CEO Dr. Vuong Trieu, developer of Abraxane, brings extensive patent expertise and successful drug development experience that strengthens the company's position in advancing innovative cancer therapies with significant market potential.
Clene's CNM-Au8 Shows Promise in Addressing Cellular Dysfunction in Parkinson's Disease
Clene Inc.'s investigational therapy CNM-Au8 demonstrates potential to improve mitochondrial health and reduce inflammation in Parkinson's disease models, offering new hope for addressing the underlying cellular mechanisms driving neurodegeneration.
LabConnect and OmniScience Partner to Launch First AI Solution for Real-Time Clinical Lab Data Analysis
LabConnect and OmniScience have partnered to create the first AI-driven platform that provides real-time insights from clinical trial lab data, potentially accelerating drug development timelines and improving trial outcomes.
UCLA Researcher Peter Tontonoz to Receive 2025 American Heart Association Basic Research Prize for Lipid Metabolism Discoveries
Dr. Peter Tontonoz's groundbreaking research on cholesterol and lipid metabolism has transformed understanding of cardiovascular diseases and paved the way for new treatments beyond statins.
Oncotelic Therapeutics Reports Two Years of Clinical Progress Across Oncology and Rare Disease Programs
Oncotelic Therapeutics has achieved significant clinical milestones over the past two years, advancing multiple late-stage programs including OT-101 for pancreatic cancer and OXi4503 for AML/MDS, positioning the company to address multi-billion-dollar markets with high unmet medical needs.
Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results
Kairos Pharma will present interim efficacy results from its Phase 2 trial of ENV105 in advanced prostate cancer, potentially addressing critical drug resistance challenges in oncology treatment.
Lantern Pharma CEO Discusses AI-Driven Cancer Drug Development on BioMedWire Podcast
Lantern Pharma's CEO Panna Sharma outlines the company's progress in using artificial intelligence to accelerate cancer drug development and transform oncology treatment approaches.
Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
Soligenix Receives FDA Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment
Soligenix Inc. has secured FDA orphan drug designation for its investigational therapy dusquetide, marking a significant advancement in treating Behçet's disease following promising phase 2a clinical trial results.
Oncotelic Therapeutics Highlights CEO's Track Record and Clinical Pipeline Advancements
Oncotelic Therapeutics showcases CEO Dr. Vuong Trieu's substantial patent portfolio and successful drug development history while updating progress on its oncology and immunotherapy pipeline.
Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease
InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Creative Biolabs Advances Biopharmaceutical Innovation Through Glycobiology Expertise
Creative Biolabs is enhancing biopharmaceutical development through advanced glycoprotein engineering and polysaccharide analysis technologies that improve drug efficacy, safety, and stability.
Clene Inc. Advances Neurodegenerative Disease Treatment CNM-Au8® Toward Potential FDA Accelerated Approval
Clene Inc. is progressing its oral treatment CNM-Au8® for ALS and multiple sclerosis through late-stage clinical development, with key FDA meetings and regulatory catalysts potentially accelerating commercialization for patients with limited treatment options.
Zevra Therapeutics to Present New MIPLYFFA Data at International Congress, Including Best Poster Award Winner
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism, including a Best Poster award-winning presentation detailing its mechanism of action for treating Niemann-Pick disease type C, highlighting significant advancements in rare disease treatment.
Oncotelic Therapeutics Highlights Robust Oncology Pipeline and CEO's Patent Portfolio
Oncotelic Therapeutics showcases its clinical-stage oncology and immunotherapy pipeline, including multiple late-stage candidates and rare disease programs, while emphasizing CEO Dr. Vuong Trieu's extensive intellectual property contributions that underpin the company's competitive strategy.
Soligenix Advances Rare Disease Pipeline with Key Clinical Milestones Expected Through 2026
Soligenix Inc. reports significant progress in its late-stage rare disease treatments, including pivotal Phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies that could transform care for underserved patient populations.
Lantern Pharma Advances Oncology Pipeline with AI-Driven Clinical Progress and Extended Financial Runway
Lantern Pharma reports significant clinical trial advancements and AI platform enhancements while maintaining strong financial discipline, positioning the company for continued oncology drug development through mid-2026.
Clene Inc. Advances Toward NDA Submission for ALS Treatment CNM-Au8, Extends Financial Runway
Clene Inc. is preparing to submit a New Drug Application for its ALS treatment candidate CNM-Au8 by year-end 2025 while securing financial stability through recent financing that extends its cash runway into early 2026.
Sethera Therapeutics Announces Enzymatic Platform for Advanced Peptide Drug Development
Sethera Therapeutics has published research on an enzymatic platform that creates stable peptide structures, potentially enabling more effective and orally deliverable peptide therapeutics.
ReAlta Life Sciences Gains EMA Orphan Drug Designation for Graft-Versus-Host Disease Treatment
ReAlta Life Sciences received European Medicines Agency Orphan Drug Designation for its drug pegtarazimod, advancing a novel dual-targeting treatment approach for steroid-refractory acute graft-versus-host disease that addresses critical unmet medical needs.
Lantern Pharma Launches AI Tool predictBBB.ai to Revolutionize CNS Drug Development with 94% Accuracy
Lantern Pharma's new AI platform predictBBB.ai addresses the critical challenge of blood-brain barrier permeability in drug development, potentially accelerating treatments for neurological diseases with unprecedented 94% prediction accuracy.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.
Ascentage Pharma Advances Global Phase III Trial for Lisaftoclax in Higher-Risk MDS Treatment
Ascentage Pharma's GLORA-4 Phase III trial of lisaftoclax, a potential breakthrough for higher-risk myelodysplastic syndrome (MDS), receives FDA and EMA clearance, marking a significant step towards addressing a critical unmet medical need in oncology.